Premium
Predicting cognitive decline in Alzheimer's disease: An integrated analysis
Author(s) -
Lopez Oscar L.,
Schwam Elias,
Cummings Jeffrey,
Gauthier Serge,
Jones Roy,
Wilkinson David,
Waldemar Gunhild,
Zhang Richard,
Schindler Rachel
Publication year - 2010
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2010.04.003
Subject(s) - donepezil , cognitive decline , placebo , disease , medicine , cognition , multivariate analysis , alzheimer's disease , multivariate statistics , psychology , dementia , demography , gerontology , psychiatry , pathology , alternative medicine , sociology , statistics , mathematics
Background Numerous patient‐ and disease‐related factors increase the risk of rapid cognitive decline in patients with Alzheimer's disease (AD). The ability of pharmacological treatment to attenuate this risk remains undefined. Methods Pooled data from 14 randomized clinical studies of donepezil in the treatment of AD (N = 3748) were analyzed to identify predictors of fast decline and determine the effect of donepezil on the risk of fast decline. Results Young age and more severe baseline cognitive, global, or behavioral status were identified as independent predictors of faster decline in placebo‐treated patients. Multivariate models indicated that donepezil treatment was associated with a 39% to 63% reduction in the risk of faster decline. Conclusions These results correspond with previous findings, indicating relationships between age or baseline disease severity and rates of cognitive decline. Furthermore, they suggest that symptomatic therapy for AD could reduce the likelihood of faster decline in treated patients.